HOME >> BIOLOGY >> NEWS
New study suggests promising drug combinations for sleeping sickness

Results from a clinical trial evaluating new drug combinations for sleeping sickness, carried out by the international humanitarian medical aid agency Medecins Sans Frontieres (MSF), and its research arm, Epicentre, have now been published in the journal PLoS Clinical Trials.

African trypanosomiasis, or sleeping sickness affects many tens of thousands of people each year in sub-Saharan Africa and is a serious disease for which there are few treatment options. The most commonly used drug, Melarsoprol, is highly toxic. MSF and Epicentre jointly carried out a trial that started in 2001 in Uganda to evaluate the efficacy and safety of three drug combinations for this disease. The aim was to find out if any of these combinations would provide a viable treatment option for patients with second-stage sleeping sickness, where infection has reached the brain and prognosis is normally very poor. In the trial the drug combinations compared were melarsoprol-nifurtimox, melarsoprol-eflornithine, and nifurtimox-eflornithine. However, once 54 patients had been recruited (435 were planned), it was obvious that the death rate was much higher amongst individuals receiving one of the combinations, so the trial was stopped.

In the trial, the cure rate for nifurtimox-eflornithine was over twice that for melarsoprol-nifurtimox and substantially higher than that for melarsoprol-eflornithine. The rates of adverse events were also lower for patients treated with nifurtimox-eflornithine. These findings are encouraging and suggest that the nifurtimox-eflornithine combination has potential as a future therapy for second-stage African trypanosomiasis, and should be evaluated further in clinical trials.


'"/>

Contact: Sarah Clark
sclark@plos.org
Public Library of Science
8-Dec-2006


Page: 1

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Clones on task serve greater good, evolutionary study shows
3. Pollution causes 40 percent of deaths worldwide, study finds
4. A study by the MUHC and McGill University opens a new door to understanding cancer
5. New study suggests Concord grape juice may provide protection against breast cancer
6. Preclinical study links gene to brain aneurysm formation
7. In limiting life span, study finds booming bacteria innocent
8. Multicenter study nets new lung tumor-suppressor gene
9. MIT study: Maturity brings richer memories
10. Chickadee, nutchatch presence in conifers increases tree growth, says CU-Boulder study
11. Phase II study of therapeutic vaccine shows efficacy in patients with metastatic colorectal cancer

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/22/2020)... ... April 21, 2020 , ... Captis Biotechnology, Inc. announced ... that provides patent development support for early stage startups. The investment will support ... ovarian cancer and precancerous pancreatic lesions with simple, accurate and practical technology. , ...
(Date:4/18/2020)... ... April 16, 2020 , ... SIRION Biotech GmbH , a world ... it will present a company update on its work expediting gene therapy research and ... on April 22 and 23. Dieter Lingelbach, the Company’s Chief Operating Officer, will also ...
(Date:4/16/2020)... , ... April 15, 2020 , ... ... working cell banks and hMSC bioprocess systems, announces that the Medical Technology Enterprise ... at MTEC’s 4th Annual Membership Meeting in March. The Regenerative Medicine (RegenMed) biomanufacturing ...
Breaking Biology News(10 mins):
(Date:5/5/2020)... ... May 05, 2020 , ... Smart Meter, ... of its iGlucose® LTE Cat-M Cellular Connected Diabetes Blood Glucose Monitor ... the industry’s newest and broadest cellular connectivity available, to provide patients with seamless ...
(Date:4/26/2020)... ... April 23, 2020 , ... Indegene Omnipresence, Inc. ... providing applications and services for use on Microsoft Azure. The customer experience management ... up online for a built-for-purpose customer engagement capability to use in their commercial ...
(Date:4/22/2020)... , ... April 20, 2020 , ... ... in Cambridge, MA, announced today that Omixon’s founder and chairman Dr. Attila Berces ... Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role ...
(Date:4/22/2020)... (PRWEB) , ... April 21, 2020 , ... ... continue their work through COVID-19. Many clinical trial teams are working remotely and ... Ripple Science wants to help researchers continue their research during this uncertain time ...
Breaking Biology Technology:
Cached News: